Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection.

TitleGluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection.
Publication TypeJournal Article
Year of Publication2010
AuthorsMarrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S
JournalProc Natl Acad Sci U S A
Volume107
Issue21
Pagination9819-24
Date Published2010 May 25
ISSN1091-6490
KeywordsAnimals, Carbon, Citric Acid Cycle, Fatty Acids, Gluconeogenesis, Macrophages, Mice, Mice, Inbred C57BL, Mycobacterium tuberculosis, Phosphoenolpyruvate Carboxykinase (GTP), Tuberculosis, Virus Replication
Abstract

Metabolic adaptation to the host niche is a defining feature of the pathogenicity of Mycobacterium tuberculosis (Mtb). In vitro, Mtb is able to grow on a variety of carbon sources, but mounting evidence has implicated fatty acids as the major source of carbon and energy for Mtb during infection. When bacterial metabolism is primarily fueled by fatty acids, biosynthesis of sugars from intermediates of the tricarboxylic acid cycle is essential for growth. The role of gluconeogenesis in the pathogenesis of Mtb however remains unaddressed. Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the first committed step of gluconeogenesis. We applied genetic analyses and (13)C carbon tracing to confirm that PEPCK is essential for growth of Mtb on fatty acids and catalyzes carbon flow from tricarboxylic acid cycle-derived metabolites to gluconeogenic intermediates. We further show that PEPCK is required for growth of Mtb in isolated bone marrow-derived murine macrophages and in mice. Importantly, Mtb lacking PEPCK not only failed to replicate in mouse lungs but also failed to survive, and PEPCK depletion during the chronic phase of infection resulted in mycobacterial clearance. Mtb thus relies on gluconeogenesis throughout the infection. PEPCK depletion also attenuated Mtb in IFNgamma-deficient mice, suggesting that this enzyme represents an attractive target for chemotherapy.

DOI10.1073/pnas.1000715107
Alternate JournalProc Natl Acad Sci U S A
PubMed ID20439709
PubMed Central IDPMC2906907
Grant ListR01AI63446 / AI / NIAID NIH HHS / United States
R01 AI063446 / AI / NIAID NIH HHS / United States
R01AI63446-03S1 / AI / NIAID NIH HHS / United States
T32 AI007621 / AI / NIAID NIH HHS / United States
T32AI007621 / AI / NIAID NIH HHS / United States

Weill Cornell Medicine Microbiology and Immunology 1300 York Avenue, Box 62 New York, NY 10065 Phone: (212) 746-6505 Fax: (212) 746-8587